Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason N Dungu

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Heart (British Cardiac Society)|August 21, 2021
Dilated cardiomyopathy: the role of genetics, highlighted in a family with Filamin C (FLNC) variantJason N Dungu, Samantha G Langley, Amy Hardy-Wallace, et al.
Open Heart|April 17, 2025
Tale of three services: early UK experience with mavacamten treatment for hypertrophic cardiomyopathy with left ventricular outflow tract obstructionEdward Burford, Yande Kasolo, Jane Draper, et al.
Journal of Cardiac Failure|April 25, 2017
Assessing the Eligibility Criteria in Phase III Randomized Controlled Trials of Drug Therapy in Heart Failure With Preserved Ejection Fraction: The Critical Play-Off Between a "Pure" Patient Phenotype and the Generalizability of Trial FindingsHitesh C Patel, Carl Hayward, Jason N Dungu, et al.
Circulation. Heart Failure|September 14, 2016
Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac AmyloidosisJason N Dungu, Sofia A Papadopoulou, Katharine Wykes, et al.
JACC. Cardiovascular Imaging|January 14, 2014
CMR-based differentiation of AL and ATTR cardiac amyloidosisJason N Dungu, Oswaldo Valencia, Jennifer H Pinney, et al.
Cardiology Journal|February 11, 2020
Stress perfusion cardiovascular magnetic resonance and serial fractional flow reserve assessment of the left anterior descending artery in patients undergoing right coronary artery chronic total occlusion revascularizationRichard E Jones, Grigoris V Karamasis, Jason N Dungu, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 24, 2018
The impact of coronary chronic total occlusion percutaneous coronary intervention upon donor vessel fractional flow reserve and instantaneous wave-free ratio: Implications for physiology-guided PCI in patients with CTOShah R Mohdnazri, Grigoris V Karamasis, Firas Al-Janabi, et al.
European Journal of Heart Failure|February 15, 2020
Predictors of left ventricular remodelling in patients with dilated cardiomyopathy - a cardiovascular magnetic resonance studyUpasana Tayal, Ricardo Wage, Simon Newsome, et al.
European Heart Journal. Cardiovascular Imaging|November 10, 2025
A double-blind, randomised placebo-controlled trial examining the effect of MitoQ on myocardial energetics in patients with dilated cardiomyopathyBrian P Halliday, Ruth Owen, Aaraby Ragavan, et al.
ESC Heart Failure|September 8, 2025
A novel treatment score (QUAD score) to promote treatment optimization in heart failure with a reduced ejection fractionHenry Oluwasefunmi Savage, Jason N Dungu, Anthony Dimarco, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Heart (British Cardiac Society)|August 21, 2021
Dilated cardiomyopathy: the role of genetics, highlighted in a family with Filamin C (FLNC) variantJason N Dungu, Samantha G Langley, Amy Hardy-Wallace, et al.
Open Heart|April 17, 2025
Tale of three services: early UK experience with mavacamten treatment for hypertrophic cardiomyopathy with left ventricular outflow tract obstructionEdward Burford, Yande Kasolo, Jane Draper, et al.
Journal of Cardiac Failure|April 25, 2017
Assessing the Eligibility Criteria in Phase III Randomized Controlled Trials of Drug Therapy in Heart Failure With Preserved Ejection Fraction: The Critical Play-Off Between a "Pure" Patient Phenotype and the Generalizability of Trial FindingsHitesh C Patel, Carl Hayward, Jason N Dungu, et al.
Circulation. Heart Failure|September 14, 2016
Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac AmyloidosisJason N Dungu, Sofia A Papadopoulou, Katharine Wykes, et al.
JACC. Cardiovascular Imaging|January 14, 2014
CMR-based differentiation of AL and ATTR cardiac amyloidosisJason N Dungu, Oswaldo Valencia, Jennifer H Pinney, et al.
Cardiology Journal|February 11, 2020
Stress perfusion cardiovascular magnetic resonance and serial fractional flow reserve assessment of the left anterior descending artery in patients undergoing right coronary artery chronic total occlusion revascularizationRichard E Jones, Grigoris V Karamasis, Jason N Dungu, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 24, 2018
The impact of coronary chronic total occlusion percutaneous coronary intervention upon donor vessel fractional flow reserve and instantaneous wave-free ratio: Implications for physiology-guided PCI in patients with CTOShah R Mohdnazri, Grigoris V Karamasis, Firas Al-Janabi, et al.
European Journal of Heart Failure|February 15, 2020
Predictors of left ventricular remodelling in patients with dilated cardiomyopathy - a cardiovascular magnetic resonance studyUpasana Tayal, Ricardo Wage, Simon Newsome, et al.
European Heart Journal. Cardiovascular Imaging|November 10, 2025
A double-blind, randomised placebo-controlled trial examining the effect of MitoQ on myocardial energetics in patients with dilated cardiomyopathyBrian P Halliday, Ruth Owen, Aaraby Ragavan, et al.
ESC Heart Failure|September 8, 2025
A novel treatment score (QUAD score) to promote treatment optimization in heart failure with a reduced ejection fractionHenry Oluwasefunmi Savage, Jason N Dungu, Anthony Dimarco, et al.
Pageof 3